当前位置: X-MOL 学术Expert Rev. Mol. Diagn. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers
Expert Review of Molecular Diagnostics ( IF 5.1 ) Pub Date : 2020-11-16 , DOI: 10.1080/14737159.2020.1842199
Esmat Abdi 1 , Saeid Latifi-Navid 1 , Fatemeh Abdi 2 , Zahra Taherian-Esfahani 3
Affiliation  

ABSTRACT

Introduction

Circulating non-coding RNAs (ncRNAs) possess high stability in circulation, making them capable of being utilized in the diagnosis, prognosis, and treatment of upper gastrointestinal (GI) tract cancers.

Areas covered

Herein, the potential clinical application of emerging circulating miRNAs and lncRNAs in upper GI cancers are comprehensively reviewed.

Expert opinion

For esophageal cancer (EC), the circulating miRNAs, miR-21, miR-223, and miR-375 have been validated as promising diagnostic biomarkers in a meta-analysis. For gastric cancer (GC), miR-17, miR-18a, miR-21, miR-25, miR-223, miR-451, and lncRNA-H19 have been reported in several studies and are likely to be promising biomarkers. Unlike EC, many circulating lncRNAs have been newly reported for GC and each is often limited to one study. They show excellent or outstanding discrimination performance, such as XIST, LOC100506474, UCA1, LINC00467, ZNFX1-AS1, HULC, AA174084, CEBPA-AS1, MIAT, PCSK2-2:1, HOTTIP, H19 (AUCs 0.8 to 0.9), and particularly CUDR, LSINCT-5, PTENP1, HOTAIR, and LncRNA-GC1 (AUCs > 0.9). Most importantly, using a group of ncRNAs as a diagnostic panel would give a more promising diagnostic or prognostic performance. However, different clinical trials and large, multi-center cohorts as well as comprehensive meta-analyses should also be conducted to validate and use emerging circulating ncRNAs as the indicators of GI cancers.



中文翻译:

上消化道癌症中新出现的循环 miRNA 和 LncRNA

摘要

介绍

循环非编码 RNA (ncRNA) 在循环中具有高稳定性,使其能够用于上消化道 (GI) 道癌症的诊断、预后和治疗。

覆盖区域

在此,全面回顾了新兴循环 miRNA 和 lncRNA 在上消化道癌症中的潜在临床应用。

专家意见

对于食管癌 (EC),循环 miRNA、miR-21、miR-223 和 miR-375 在荟萃分析中已被证实为有希望的诊断生物标志物。对于胃癌 (GC),miR-17、miR-18a、miR-21、miR-25、miR-223、miR-451 和 lncRNA-H19 已在多项研究中得到报道,并且可能是有前景的生物标志物。与 EC 不同,许多循环 lncRNA 已被新报告用于 GC,并且每个通常仅限于一项研究。它们显示出优秀或出色的辨别性能,例如 XIST、LOC100506474、UCA1、LINC00467、ZNFX1-AS1、HULC、AA174084、CEBPA-AS1、MIAT、PCSK2-2:1、HOTTIP、H19(AUCs 0.8 至 0),尤其是 09。 CUDR、LSINCT-5、PTENP1、HOTAIR 和 LncRNA-GC1(AUC > 0.9)。最重要的是,使用一组 ncRNA 作为诊断面板将提供更有希望的诊断或预后性能。然而,

更新日期:2020-12-05
down
wechat
bug